ATHIRA PHARMA, INC. |
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 2.595 USD | -1.70% |
|
+11.11% | +7.00% |
| 06-18 | Transcript : Athira Pharma, Inc. - Special Call | |
| 06-12 | Transcript : Athira Pharma, Inc. Presents at Goldman Sachs 45th Annual Global Healthcare Conference, Jun-12-2024 02:00 PM |
Presentation Operator MessageOperator (Operator)Welcome to Athira Pharma's webinar, Lead up to...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
Athira Pharma, Inc. is a late clinical-stage biopharmaceutical company. It focuses on developing small molecules engineered to restore neuronal health and slow neurodegeneration. Its pipeline consists of both blood brain barrier permeable and peripherally restricted drug candidates for the central nervous system (CNS), peripheral nervous system, and other indications. Its lead candidate, fosgonimeton (ATH-1017), is a subcutaneously administered, small molecule positive modulator of the hepatocyte growth factor/mesenchymal-epithelial transition factor (HGF/MET) system for CNS disorders. It is also evaluating other drug candidates for the potential treatment of neuropathic pain, amyotrophic lateral sclerosis, Parkinson's disease, and other neurodegenerative diseases. Its ATH-1020 has completed a Phase I single ascending dose evaluation in healthy volunteers. Its ATH-1105 is a small molecule compound designed to be an orally available, once-daily treatment to enhance the HGF/MET system.
Calendar
2024-08-11
- Q2 2024 Earnings Release (Projected)
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
6
Last Close Price
2.64
USD
Average target price
7.275
USD
Spread / Average Target
+175.57%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +7.00% | 101M | |
| +39.02% | 39.1B | |
| -7.36% | 38.76B | |
| +26.99% | 31.24B | |
| +12.78% | 25.9B | |
| -13.75% | 25.8B | |
| +46.00% | 14.06B | |
| +39.88% | 13.12B | |
| -6.05% | 11.32B | |
| -11.57% | 10.68B |
- Stock Market
- Equities
- ATHA Stock
- News Athira Pharma, Inc.
- Transcript : Athira Pharma, Inc. - Special Call
